Get the Stockscreener App
6.68
5.03%
0.32
Yd Bio Ltd stock is traded at $6.68, with a volume of 66,083.
It is up +5.03% in the last 24 hours and up +69.11% over the past month.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.
See More
Previous Close:
$6.36
Open:
$6.3
24h Volume:
66,083
Relative Volume:
0.30
Market Cap:
$473.23M
Revenue:
Net Income/Loss:
$-2.97M
P/E Ratio:
-6.7611
EPS:
-0.988
Net Cash Flow:
$-1.18M
1W Performance:
+15.37%
1M Performance:
+69.11%
6M Performance:
+22.91%
1Y Performance:
-64.60%
1-Day Range:
$6.30
$6.8699
1-Week Range:
$5.61
$7.13
52-Week Range:
$1.70
$22.00
Yd Bio Ltd Stock (YDES) Company Profile
Compare YDES vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
6.68 | 473.23M | 0 | -2.97M | -1.18M | -0.988 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Yd Bio Ltd Stock (YDES) Latest News
YD Bio Limited Ordinary Shares (YDES) Stock Price: Oct 7 Close $5.88 - Gotrade
Quarterly stock vesting brings Kochi Chang's direct YD Bio (YDES) holding to 10,965 shares. - Stock Titan
YD Bio (Nasdaq:YDES)Stock Analysis - Simply Wall Street
Unusual volume stocks are being observed in Thursday's session. - ChartMill
Unusual Volume Scan: Recent Session US Stock Movers Above 50-Day Average Volume - ChartMill
Enterprise value to revenue forward of YD Bio Limited – BOATS:YDESW - TradingView
Unusual volume stocks in Tuesday's session - ChartMill
YD Bio Limited (YDES) Edges Higher as Shares Hold Above Key SupportPrice Momentum Stocks - dars.gov.et
YD Bio Limited (YDES) Edges Higher as Shares Hold Above Key SupportTRIN Signal - dars.gov.et
YD Bio Limited (YDES) Edges Higher as Shares Hold Above Key SupportMACD Signal Stocks - www.dars.gov.et
YD Bio Limited H1 2026 Earnings: Revenue Soars 315% to $0.85M as Warrant Revaluation Drives $6.70M Profit - technotrenz.com
YD Bio posts $6.7M profit but flags going concern | YDES SEC FilingForm 6-K - Stock Titan
YD Bio Ord Shs (YDES) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
YD Bio (YDES) Earnings Date and Reports 2026 - marketbeat.com
YD Bio H1FY26 Results: Revenue up 315%, net profit turns positive - scanx.trade
YD Bio Limited Reports First-Half 2026 Financial Results, 315% Revenue Growth and Net Income of $6.7 Million - Quiver Quantitative
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026 - Yahoo Finance
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
YD Bio Limited (YDES) Edges Lower to $4.60 as Biotech Pullback Tests Key Support ZoneVolatility Smirk - dars.gov.et
YD Bio Announces Peer-Reviewed Publication in Nutrients, Co-Authored with Physicians from the Taiwan Chronic Disease Healthcare Association and the Future Health Institute - Yahoo Finance
YD (YDESW) Watch: Adds 10.81% to Close at $0.41; the Near-Term Reference Band Stretches From $0.39 to $0.43 in the Current UpdateMoving Average Ribbon - vinanet.vn
YD (YDES) Watch: Retreats 2.00% to $4.69; Price Setup: the Price Remains Bounded by the Supplied Support and Resistance in the Current UpdateDealer Positioning - vinanet.vn
YD (YDES) Market: Moves 6.46% Up to $4.24 for the Current Session; Market Levels: $4.03 and $4.45 Define the Nearby Reference Levels in the Latest SessionJelly Roll Trade - https://www.siam.in/
YD (YDES) Market: Moves 6.46% Up to $4.24 for the Current Session; Market Levels: $4.03 and $4.45 Define the Nearby Reference Levels in the Latest SessionAlgorithmic Stock Picks - dars.gov.et
ETFs Investing in YD Bio Limited Stocks - TradingView
Top movers in Tuesday's pre-market session - ChartMill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
After-Hours Gainers: PFSA Executes Another Reverse Split, IVF Jumps On Q2 Results, AMLX Faces D-Day - RTTNews
YD Bio Limited (YDES) Surges 13% as Shares Push Toward Key ResistancePCR Divergence - vinanet.vn
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
YD Bio Launches Physician-Led Nutraceuticals in Taiwan to Build Consumer Health Ecosystem - TipRanks
YD Bio launches nutrition products via physician partnership model By Investing.com - Investing.com Australia
YD Bio launches nutrition products via physician partnership model By Investing.com - Investing.com South Africa
YD Bio launches nutrition products via physician partnership model - Investing.com
YD Bio Launches a Physician-Partnership Initiative in Taiwan with the Announcement of Two Nutraceutical Products in Collaboration with the Taiwan Chronic Disease Healthcare Association and the Future Health Institute - Yahoo Finance
YD Bio launches nutrition products via physician partnership model By Investing.com - Investing.com Canada
Top YD Bio (YDES) Competitors 2026 - MarketBeat
YD Bio Ord Shs (YDES) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
YD Bio Ord Shs (YDES) Stock News Today - TradingKey
Lantheus Holdings (LNTH) Holds Near $101 as Buyers Defend Key SupportForce Index - vinanet.vn
YD Bio Highlights Peer-Reviewed Publication on New Computational Framework for Keratoconus Research - Yahoo Finance
YD Bio Limited (YDES) Holds Steady at $2.31 — Key Support and Resistance in FocusInstitutional Buy Signals - vinanet.vn
YD Bio (YDES) Insider Trading Activity 2026 - marketbeat.com
YD Bio Launches Cross-Border Cancer Testing Pilot in Canada - Clinical Lab Products
YD Bio Warrants (YDESW) Hold Steady at $0.25 as Tight Range Caps GainsBullish Sentiment - vinanet.vn
YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada - The Manila Times
YD Bio launches pilot for cancer testing in British Columbia By Investing.com - Investing.com Canada
Five Cancer Types Targeted in YD Bio's Cross-Border Pilot - Stock Titan
Y.D. More group (TATT) reports 5.42% beneficial stake in TAT Technologies - Stock Titan
Yd Bio Ltd Stock (YDES) Financials Data
Revenue
Net Income
Cash Flow
EPS
Yd Bio Ltd Stock (YDES) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shen Ethan PhD | CEO |
Sep 09 '26 |
Buy |
3.93 |
3,100 |
12,183 |
11,245,631 |
| Shen Ethan PhD | CEO |
Sep 04 '26 |
Buy |
3.67 |
18,378 |
67,447 |
11,242,531 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):